Secukinumab shows reassuring low immunogenicity
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15332
Abstract: documenting strong expression of IL-17A in the lesional epidermis of patients with pustular psoriasis. However, the results of the above-mentioned trials must be interpreted with caution, as both were designed as uncontrolled, openlabel studies. In… read more here.
Keywords: gpp; shows reassuring; treatment; severity ... See more keywords
Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate‐to‐severe plaque‐type psoriasis: SUPREME study
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Dermatology"
DOI: 10.1111/bjd.16705
Abstract: Understanding genetic variations is important in predicting treatment response and forms the basis for identifying new pharmacogenetic and pharmacogenomic targets for psoriasis treatment. There are limited data on the efficacy of secukinumab in relation to… read more here.
Keywords: efficacy irrespective; shows high; irrespective hla; high efficacy ... See more keywords
Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5‐year results from the randomized placebo‐controlled TRANSFIGURE study *
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Dermatology"
DOI: 10.1111/bjd.19262
Abstract: Secukinumab, a fully human monoclonal antibody that selectively neutralizes interleukin‐17A, a cornerstone cytokine in psoriasis, has shown long‐lasting efficacy and safety in the complete spectrum of psoriasis manifestations. read more here.
Keywords: shows high; efficacy; high sustained; secukinumab shows ... See more keywords